PKC-theta inhibitors are primarily explored for their potential in modulating immune responses, making them significant in the field of immunology and autoimmune diseases. By targeting PKC-theta, these inhibitors can suppress T-cell activation, which is crucial in conditions like rheumatoid arthritis, psoriasis, and multiple sclerosis. Research is ongoing to evaluate their efficacy in reducing inflammation and autoimmune reactions without compromising the overall immune system. Additionally, PKC-theta inhibitors are being studied for their role in cancer immunotherapy, as they may help in regulating tumor-infiltrating lymphocytes and enhancing anti-tumor immune responses. Their application in transplant medicine is also under investigation, aiming to prevent organ rejection by controlling T-cell-mediated immune responses. Overall, PKC-theta inhibitors hold promise as therapeutic agents in various immune-related disorders.